These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM. Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216 [Abstract] [Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group. Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547 [Abstract] [Full Text] [Related]
14. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R. Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455 [Abstract] [Full Text] [Related]
15. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B. J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962 [Abstract] [Full Text] [Related]
16. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402 [Abstract] [Full Text] [Related]
17. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schäuble B, Trott GE. Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):554-60. PubMed ID: 21185347 [Abstract] [Full Text] [Related]
18. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B. Curr Med Res Opin; 2011 Mar 30; 27 Suppl 2():35-44. PubMed ID: 21787126 [Abstract] [Full Text] [Related]
19. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. Eur Neuropsychopharmacol; 2013 Oct 30; 23(10):1208-18. PubMed ID: 23332456 [Abstract] [Full Text] [Related]